Benefit‐risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
Langley R, Strober B, Gu Y, Rozzo S, Okun M. Benefit‐risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal Of Dermatology 2010, 162: 1349-1358. PMID: 20394634, DOI: 10.1111/j.1365-2133.2010.09707.x.Peer-Reviewed Original ResearchConceptsTumor necrosis factorAdverse eventsTumor necrosis factor antagonistsMalignant adverse eventsOpen-label dataPlacebo-controlled periodAnti-TNF therapyNecrosis factor antagonistsTreatment of psoriasisTreatment effect dataBenefit-risk balanceBenefit-risk assessmentTNF antagonistsNNT valuesEfficacy measuresClinical trialsNecrosis factorSerious toxicitySafety dataFactor antagonistsLower riskEtanerceptPsoriasisAdalimumabInfliximab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply